Objective: The aim of this study was to determine the prevalence and computed tomography (CT) features of malignancy in incidental focal fundal gallbladder wall thickening.
F ocal gallbladder wall thickening may be incidentally encountered on abdominal computed tomography (CT) performed for other reasons. The differential diagnosis for focal gallbladder wall thickening includes benign etiologies such as focal adenomyomatosis, benign polyps, and localized chronic cholecystitis, as well as malignant etiologies such as gallbladder cancer, lymphoma, and metastases. 1 In particular, the fundus is the most common location for focal adenomyomatosis, a benign condition that is typically asymptomatic and usually requires no treatment or follow-up. 2 Adenomyomatosis is also a relatively common entity, seen in 2% to 8% of cholecystectomy specimens. 3 Although gallbladder carcinoma is less common than adenomyomatosis and other benign etiologies of focal gallbladder wall thickening, it is an aggressive cancer with 5-year survival rates of 5% to 10%. 4 However 5-year survival rates up to 100% have been reported for stage T1 tumor following cholecystectomy. 5 Thus, distinguishing early-stage gallbladder cancer from benign disease in crucial.
Unfortunately, the distinction between gallbladder cancer and benign diseases such as adenomyomatosis can be challenging at CT. Gallbladder cancer can present as a polypoid mass or a mass replacing the gallbladder, in which cases the appropriate management has been established. 6, 7 However, gallbladder cancer can also present as focal or diffuse wall thickening, which may have a similar appearance to benign causes of wall thickening. Intramural cystic spaces are the classic feature of adenomyomatosis and are well demonstrated by T2-weighted magnetic resonance imaging (MRI). 8 When the cystic spaces are seen within an area of wall thickening at CT, the diagnosis of adenomyomatosis can be made with confidence. 9 However, because of the limited contrast resolution of CT compared with MRI, the cystic spaces are often not seen at CT, and it may not be possible to distinguish adenomyomatosis and gallbladder cancer. The gallbladder wall enhancement pattern has also been a reported feature to distinguish benign from malignant wall thickening. 10 The CT features that might help distinguish benign from malignant gallbladder wall thickening specifically confined to the fundus have not been examined. Therefore, the purposes of this study were to determine the prevalence of malignancy in incidental focal fundal gallbladder wall thickening seen at CT and to determine which CT features, if any, predict malignancy.
MATERIALS AND METHODS

Patient Population
We performed a retrospective study, which was approved by our institutional review board and was Health Insurance Portability and Accountability Act compliant. We performed a search of the radiology database for patients 18 years or older who underwent contrast-enhanced CT of the abdomen from April 1, 2002, to January 18, 2017. The phrases "focal fundal," fundal wall thickening," "adenomyomatosis," and "gallbladder mass" were queried. The radiology reports were first reviewed to ensure there was a description of focal fundal gallbladder wall thickening, and this yielded 240 patients. One hundred twenty patients were excluded because of a lack of follow-up imaging. The images were then reviewed to exclude cases of polypoid masses (n = 3) or masses with clear invasion into the liver (n = 1). The remaining 116 patients (mean age, 64.3 years; 49 men, 67 women) were included in the study. The reference standard for the presence or absence of malignancy was follow-up ultrasound or MRI diagnostic of the etiology of the wall thickening (n = 19), stability on CT for at least 1 year (n = 84), or pathological correlation (n = 13). The indications for the index CT are presented in Table 1 .
Imaging Technique
Owing to the length of the study period, index CT examinations were performed on a variety of CT scanners. Multidetector row CT scanners included GE 16-and 64-detector-row scanners (General Electric Medical Systems, Milwaukee, Wis) and Siemens 64-and 128-detector-row scanners (Siemens Medical System, Forchheim, Germany). All scans were obtained using a fixed kV of 120 and variable mAs using automated dose modulation. The pitch varied across the scanners. All examinations were reconstructed at slice thicknesses/intervals of 5/5 mm, and 98 examinations were also reconstructed at slice thicknesses/ intervals 1.25/1.25 mm owing to a change in our protocols during the study period. One hundred twelve index CT examinations were performed in the portal venous phase, and 4 were performed in the arterial phase. Omnipaque-350 (GE Healthcare, Cork, Ireland) was injected intravenously at a dose of 100 to 150 mL using a power injector at a rate of 2 to 4 mL/s.
The follow-up ultrasounds were performed by Registered Diagnostic Medical Sonographer-licensed technologists using Acuson Sequoia (Siemens Medical Solutions, Mountain View, Calif ) or LOGIQ E9 (GE Healthcare, Milwaukee, Wis) ultrasound machines. A variety of probes including curved, linear, and vector (low and high frequency) were utilized, depending on penetration. 
Image Analysis
Two radiologists with subspecialty training in abdominal imaging (with 8 and 6 years of post-training experience) independently reviewed the images and categorized the focal fundal gallbladder wall thickening into 1 of 6 morphological types: type 1 (nodular or pinched appearance with smooth inner layer wall enhancement and homogeneous intramural low attenuation without discrete cystic spaces), type 2 (smooth inner layer wall enhancement and homogeneous intramural low attenuation without discrete cystic spaces), type 3 (full-thickness homogeneous wall enhancement), type 4 (nodular or pinched with full-thickness homogeneous wall enhancement), type 5 (definite discrete intramural cystic spaces), and type 6 (hyperenhancing or heterogeneous wall enhancement involving any part of the thickened wall without discrete cystic spaces) (Figs. 1-6 ). Any discrepancies were resolved by consensus between the same 2 reviewers. Both axial and coronal images were available for review, and thin (1.25 mm) axial images were available for review in 98 cases. The maximal wall thickness was measured on the axial images by a single reviewer. Measurements were taken perpendicular to the wall at the point of maximal thickness. Imaging Follow-up
The original radiology reports and images of any follow-up ultrasound (n = 5) or MRI (n = 14) were reviewed by 1 radiologist. A definite diagnosis of adenomyomatosis was made on ultrasound if there was focal fundal wall thickening with intramural echogenic foci demonstrating "comet-tail" artifact. A definite diagnosis of adenomyomatosis was made on MRI if there were intramural cystic spaces seen as hyperintense on T2-weighted images within the focal fundal wall thickening. The diagnosis of malignancy was not made on ultrasound alone. The diagnosis of possible malignancy was made on MRI if there was fullthickness or heterogeneous wall enhancement without intramural cystic spaces on T2-weighted imaging.
Imaging stability was assessed on follow-up CT of the chest (n = 6) or abdomen (n = 78) that adequately showed the gallbladder fundus. Stability was defined as no change in the degree of wall thickening across the studies with a minimum of 1-year follow-up. The mean time to follow-up CT was 3.4 ± 2.4 years (range, 1-10.3 years).
Statistical Analysis
Two-sided 95% confidence intervals (CIs) were calculated using binomial exact method. For ratios with numerators of 0, 1-sided 95% CIs were used. An unpaired Student t test was used to compare wall thickness between benign and malignant lesions. Intraclass correlation coefficients with 95% CIs were calculated to assess interreader agreement for wall thickening type.
RESULTS
There were 116 patients included in the study. The mean thickness of the malignant lesions was 15.8 ± 8.1 mm (range, 8-25 mm), which was significantly greater than that of the benign lesions at 9.0 ± 3.1 mm (range, 4-18 mm) (P < 0.0001).
The number of benign and malignant or possibly malignant cases for each morphology is presented in Table 2 . Malignancy or possible malignancy was seen in 4 of 116 (3.4%; 95% CI, 0.9%-8.6%). Three of the malignant cases had type 6 morphology; 1 case was pathologically proven gallbladder adenocarcinoma, 1 had positive peritoneal cytology for gastrointestinal tract adenocarcinoma in the setting of the gallbladder lesion and was being treated for gallbladder cancer, and the third had a follow-up MRI showing an enhancing mass suggestive of malignancy. The other case had type 3 morphology and both a followup MRI and an endoscopic ultrasound showing a mass suggestive of malignancy. The 2 patients without any pathologic correlation died before any further follow-up was obtained.
The remaining 112 cases were all benign. Pathology was available in 11 benign cases with 6 cases of chronic cholecystitis, 4 cases of adenomyomatosis, and 1 case with no specific diagnosis but negative for malignancy. Follow-up imaging with diagnostic results was available in 17 benign lesions (12 MRI and 5 ultrasound), all of which showed adenomyomatosis. The morphologies for the 21 cases of adenomyomatosis (diagnosed by pathology or definitive imaging) were as follows: type 1 (n = 12), type 4 (n = 4), type 5 (n = 3), and type 6 (n = 2). Follow-up CT was performed in 84 patients, and the lesions were stable in 81 and resolved in 3.
The intraclass correlation coefficient for wall thickening type was 0.85 (95% CI, 0.81-0.89) showing good agreement between the 2 readers. There was a discrepancy in morphology type between the 2 readers in 15 of 116 cases. All of these 15 cases were benign lesions, and there was perfect agreement on the morphology type in all 4 malignant cases.
DISCUSSION
The results of this study confirm that focal fundal gallbladder wall thickening is most often due to benign entities. We propose a morphologic classification system based on contrast-enhanced CT features that help distinguish benign and malignant etiologies.
Approximately 3% (4/116) of cases of focal fundal gallbladder wall thickening in our study were malignant or potentially malignant. Thirty percent of the cases (3/10) with heterogeneous wall enhancement (type 6) and 17% (1/6) of the cases with fullthickness wall enhancement (type 3) were malignant. Therefore, these types should be considered as suggestive of malignancy when encountered, although benign etiologies remain possible. No cases of malignancy were seen when intramural cystic spaces were seen (type 5), and these were most likely cases of focal fundal adenomyomatosis. No cases of malignancy were seen when smooth inner layer enhancement and homogeneous intramural low attenuation was demonstrated, with (type 1, 0/57) or without (type 2, 0/10) a nodular/pinched appearance. These were also likely cases of focal fundal adenomyomatosis. This is supported by the finding that 12 cases with type 1 morphology had pathology or imaging confirmation of adenomyomatosis. We hypothesize that the intramural low attenuation actually represents the small cystic spaces that are below the resolution of CT to clearly delineate. No cases (0/19) of malignancy were found with a nodular/pinched appearance with full-thickness enhancement appearance (type 4). Some of these cases proved to be focal fundal adenomyomatosis and again may represent cases where the cystic spaces and even any low attenuation in the wall cannot be visualized by CT. However, the pattern is similar to full-thickness wall enhancement (type 3) where 1 malignant lesion was seen, and because of the small number of lesions in the type 4 group, it is possible that malignancy could also have this appearance. Malignant focal fundal gallbladder wall thickening was, on average, thicker than benign causes; however, there was significant overlap between the 2 groups. The smallest thickness in the malignant group was 8 mm, and thus minimal wall thickening less than this is likely to be benign. This may be a useful feature as morphologic assessment may be more difficult with lesser degrees of wall thickening.
Although our study is the first to specifically examine the risk of malignancy in focal fundal gallbladder wall thickening, our findings are similar to prior studies evaluating generalized gallbladder wall thickening. Our findings are in keeping with the study by Ching et al, 9 which showed high specificity of intramural cystic spaces seen on CT for gallbladder adenomyomatosis. However, when cystic spaces were not visualized, the accuracy of CT was low for distinguishing adenomyomatosis from malignancy in that study. Kim et al 10 described 5 different patterns of flat gallbladder wall thickening (not isolated to the fundus) and found a heterogeneous pattern of wall enhancement to be associated with malignancy, in keeping with our results. That study also found a strongly enhancing inner wall layer to be associated with malignancy, and wall hyperenhancement was included in our type 6 morphology. However, the remainder of patterns in that study did not readily apply to the morphologic types seen with isolated focal fundal gallbladder wall thickening in our study. Yun et al 11 found greater wall thickness in gallbladder malignancy versus chronic cholecystitis, which is also consistent with our findings. That study also found hyperenhancement of the inner wall on arterial phase CT to be associated with malignancy. Our study did not assess this feature as no arterial phase was acquired with our CT protocols, which were portal venous phase only given that our cases were incidentally detected. A study by Kim et al 12 specifically evaluated focal fundal gallbladder wall thickening on CT and found an oval contour, cystic spaces, and inner layer enhancement more commonly in adenomyomatosis compared with chronic cholecystitis. The oval contour likely corresponds to the nodular or pinched appearance described in our study. However, our study did not assess the differences between the various benign causes of wall thickening, and the study by Kim et al 12 did not evaluate the CT features of focal fundal malignancy.
The results of our study will aid in the management of incidentally detected focal fundal gallbladder wall thickening on CT. If focal thickening with benign morphology is encountered, we suggest that no follow-up is required. However, if type 6, type 3, and potentially type 4 patterns are encountered, additional follow-up imaging with ultrasound or MRI is warranted. If further tests are not diagnostic of a benign entity, close follow-up or surgical resection should be considered. We feel that our classification system can be widely utilized as there was good agreement on morphology type by the 2 readers. Importantly, there was no disagreement between the readers in malignant cases.
Our retrospective study has limitations. We had a small sample size, and pathologic proof was not available for most cases of focal fundal gallbladder wall thickening, including 2 cases of suspected malignancy. A definitive imaging diagnosis was also not available in most cases, and benignity was established by stability in the majority of cases where the underlying etiology of the wall thickening is not known. However, we feel that stability on CT for at least 1 year (with a mean of 3.4 years in this study) is sufficient to exclude the possibility of an aggressive malignancy such as gallbladder carcinoma. The outcomes of patients without follow-up are unknown. The CT protocols including slice thickness were not uniform because of the length of the study.
In conclusion, incidentally detected focal fundal gallbladder wall thickening is most often benign, and CT morphologic features help distinguish benign from malignant etiologies. Heterogeneous or fullthickness wall enhancement patterns should raise suspicion for malignancy, while smooth inner wall enhancement with homogeneous intramural low attenuation or cystic spaces can be considered benign.
